Cohort characteristics
| . | Patients . | |
|---|---|---|
| Characteristic . | n . | % . |
| Full cohort, n | 295 | 100 |
| Recipient age, median (range) | 66 (6-76) | |
| Recipient sex | ||
| Female | 117 | 40 |
| Male | 178 | 60 |
| HCT-CI score | ||
| 0 | 83 | 28 |
| 1-2 | 81 | 27 |
| 3+ | 120 | 40 |
| Missing | 11 | 4 |
| Type of AML (clinically defined) | ||
| De novo | 173 | 59 |
| Secondary | 91 | 31 |
| Therapy-related | 31 | 11 |
| Cytogenetics* | ||
| Normal | 136 | 46 |
| Core binding factor | 6 | 2 |
| Complex karyotype | 41 | 14 |
| Other | 112 | 38 |
| 2017 ELN risk group | ||
| Favorable | 53 | 18 |
| Intermediate | 85 | 29 |
| Adverse | 152 | 52 |
| Missing | 5 | 2 |
| Initial therapy | ||
| Intensive induction | 249 | 84 |
| Non-intensive induction | 46 | 16 |
| Reinduction | ||
| Yes | 90 | 31 |
| No | 204 | 69 |
| Missing | 1 | 0.3 |
| Remission quality | ||
| CR with hematologic recovery | 225 | 75 |
| CRi | 67 | 23 |
| Missing | 1 | 0.3 |
| Donor type | ||
| Matched related | 54 | 18 |
| Matched unrelated | 154 | 52 |
| Mismatch related | 7 | 2 |
| Mismatch unrelated | 29 | 10 |
| Haploidentical | 51 | 17 |
| Conditioning regimen | ||
| Myeloablative | 28 | 9 |
| Reduced intensity | 267 | 91 |
| T-cell depletion | 25 | 9 |
| Stem cell source | ||
| Peripheral blood | 216 | 73 |
| Bone marrow | 71 | 24 |
| Umbilical cord blood | 8 | 3 |
| . | Patients . | |
|---|---|---|
| Characteristic . | n . | % . |
| Full cohort, n | 295 | 100 |
| Recipient age, median (range) | 66 (6-76) | |
| Recipient sex | ||
| Female | 117 | 40 |
| Male | 178 | 60 |
| HCT-CI score | ||
| 0 | 83 | 28 |
| 1-2 | 81 | 27 |
| 3+ | 120 | 40 |
| Missing | 11 | 4 |
| Type of AML (clinically defined) | ||
| De novo | 173 | 59 |
| Secondary | 91 | 31 |
| Therapy-related | 31 | 11 |
| Cytogenetics* | ||
| Normal | 136 | 46 |
| Core binding factor | 6 | 2 |
| Complex karyotype | 41 | 14 |
| Other | 112 | 38 |
| 2017 ELN risk group | ||
| Favorable | 53 | 18 |
| Intermediate | 85 | 29 |
| Adverse | 152 | 52 |
| Missing | 5 | 2 |
| Initial therapy | ||
| Intensive induction | 249 | 84 |
| Non-intensive induction | 46 | 16 |
| Reinduction | ||
| Yes | 90 | 31 |
| No | 204 | 69 |
| Missing | 1 | 0.3 |
| Remission quality | ||
| CR with hematologic recovery | 225 | 75 |
| CRi | 67 | 23 |
| Missing | 1 | 0.3 |
| Donor type | ||
| Matched related | 54 | 18 |
| Matched unrelated | 154 | 52 |
| Mismatch related | 7 | 2 |
| Mismatch unrelated | 29 | 10 |
| Haploidentical | 51 | 17 |
| Conditioning regimen | ||
| Myeloablative | 28 | 9 |
| Reduced intensity | 267 | 91 |
| T-cell depletion | 25 | 9 |
| Stem cell source | ||
| Peripheral blood | 216 | 73 |
| Bone marrow | 71 | 24 |
| Umbilical cord blood | 8 | 3 |
Shown are the pretransplant characteristics of the 295 patients included in the cohort. HCT-CI: hematopoietic cell transplant comorbidity index score. CRi denotes complete remission with incomplete recovery of at least 1 hematopoietic cell lineage.
ELN, European Leukemia Network.
Core binding factor: inv(16) or t(8;21); complex karyotype: 3 or more chromosomal abnormalities within a single clone.